Helga Droogendijk

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld et al. · The Lancet Oncology · 2023 · 168 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16

Imatinib mesylate in the treatment of systemic mastocytosis

Helga Droogendijk, Hanneke C. Kluin‐Nelemans, J. J. van Doormaal et al. · Cancer · 2006 · 148 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +14

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis

Jonathan E. Knikman, Tycho A. Wilting, Marta López‐Yurda et al. · Journal of Clinical Oncology · 2023 · 55 citations · Full text

Medicine, Oncology, Pharmacology +16